Status:
RECRUITING
Investigating a Tailored Diuretic Algorithm in Acute Heart Failure Patients
Lead Sponsor:
Zuyderland Medisch Centrum
Conditions:
Heart Failure Acute
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Acutely decompensated heart failure (ADHF) is highly prevalent and has a high (financial) burden on the health care system. Treatment often consists of the administration of IV decongestive agents. Ad...
Detailed Description
Rationale: Acutely decompensated heart failure is a highly prevalent diagnosis with a high burden on resources and a high risk of mortality and re-hospitalization. The prescription of diuretics to rel...
Eligibility Criteria
Inclusion
- Age \> 18 years;
- HF (HFrEF, HFmrEF or HFpEF) diagnosed according to the 2021 HF Guidelines of the European Society of Cardiology \[5\];
- Presentation with AHF meaning at least one symptom (dyspnea, orthopnea, or edema) and one sign (rales, peripheral edema, ascites, or pulmonary vascular congestion on chest radiography) of AHF;
- An elevated NT-proBNP \>300pg/ml;
- Requiring the need for iv diuretics.
Exclusion
- Terminal renal insufficiency defined as: dialysis patients or eGFR (estimated glomerular filtration rate) \< 10 mL/min/1.73 m2;
- Patients included in other investigational studies regarding heart failure.
- Presentation with cardiogenic shock or respiratory insufficiency or another reason requiring admission to the intensive care unit upon admission (IC transfer later in the hospitalization is not an exclusion).
Key Trial Info
Start Date :
February 27 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 27 2026
Estimated Enrollment :
466 Patients enrolled
Trial Details
Trial ID
NCT06092437
Start Date
February 27 2023
End Date
August 27 2026
Last Update
August 6 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Zuyderland MC
Heerlen, Limburg, Netherlands, 6419 PC
2
Amphia ziekenhuis
Breda, North Brabant, Netherlands, 4818 CK